Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Fluctuating Methylation-based ctDNA Detection in NSCLC Surveillance: Implications for Serial Monitoring and Specificity.

Created on 16 Nov 2026

Authors

Jae M Cho, Guy Clark, Molly Bogardus, Rachel Cox, Juliana Melchionda, David Barbie, Cloud P Paweletz, Hassan A Khalil

Published in

JTO clinical and research reports. Volume 7. Issue 12. Pages 101081. Epub Sep 18, 2026.

Abstract

Circulating tumor DNA (ctDNA) addresses key limitations of traditional radiographic and tissue-based screening by providing a noninvasive alternative for the surveillance of NSCLC. In our study, we aim to evaluate trends in the performance of a commercially available methylation-based ctDNA test, characterize patient factors associated with fluctuating ctDNA positivity, and evaluate the clinical implications of serial monitoring.
This retrospective observational cohort study included patients who underwent lung resection or stereotactic body radiation therapy for NSCLC followed by posttreatment ctDNA testing from 2024 to 2025. The primary outcomes include patient- and tumor-related risk factors associated with ctDNA positivity. A subgroup analysis of the ctDNA-positive group evaluated clinical events and genomic profiling that may influence transient ctDNA positivity.
Of the 85 patients studied, 17 (20%) had at least one positive ctDNA test. Both ctDNA-positive and negative groups had similar patient and tumor-related features. Ten (59%) patients with a positive result subsequently tested negative, and 11 (65%) had a ctDNA tumor fraction near the limit of detection (LOD) without radiographic recurrence. No consistent associations were found with timing, adjuvant therapy, inflammatory markers, or tumor genomics. Three patients with ctDNA fractions above the limit of detection had confirmed recurrence; none in the ctDNA-negative group had disease recurrence.
Although the utility of serial ctDNA testing is promising for NSCLC surveillance, isolated low-level positivity may not warrant clinical action. We observe frequent low-level, transient ctDNA positivity without radiographic evidence of recurrence, suggesting limitations in assay specificity and need for trend-based interpretation instead of isolated testing.

PMID:
43036776
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement